LIPELLA PHARMACEUTICALS INC(NASDAQ:LIPO) stock News

LIPO Latest News, Press Relases and Analysis

All

Press Releases

3 months ago - By: Benzinga - Mentions: SPTN IBO CMPS CDTX ...

Crude Oil Falls 1%; US Services PMI Declines In June

3 months ago - By: Benzinga - Mentions: FDS SANW IBO CMPS ...

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

3 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

3 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

11 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

4 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

5 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

5 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

5 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

6 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

6 months ago - By: Spartan Capital Securities, LLC - Mentions: HCTI

Spartan Capital Securities, LLC Announces Key February Transactions

6 months ago - By: Spartan Capital Securities, LLC

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement

7 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

7 months ago - By: Stocktwits - Mentions: GHRS MBX RANI IVVD

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

7 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

8 months ago - By: Spartan Capital Securities, LLC

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

9 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

10 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

10 months ago - By: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

11 months ago - By: Lipella Pharmaceuticals Inc.

LIPELLA PHARMACEUTICALS INC (LIPO) Stock News

LIPO Latest News, Press Relases and Analysis

Crude Oil Falls 1%; US Services PMI Declines In June

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Spartan Capital Securities, LLC Announces Key February Transactions

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $3,788,000 Private Placement

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference